C3N-02087
— · cohortA1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortA1
- subtype
- cohortA1
- age_years
- 61.41820671
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.640
- INTERFERON_GAMMA_RESPONSE+0.600
- ALLOGRAFT_REJECTION+0.490
- IL6_JAK_STAT3_SIGNALING+0.490
- INFLAMMATORY_RESPONSE+0.450
- PROTEIN_SECRETION+0.450
- OXIDATIVE_PHOSPHORYLATION+0.420
- TNFA_SIGNALING_VIA_NFKB+0.410
- MTORC1_SIGNALING+0.390
- APOPTOSIS+0.380
Top 10 suppressed
- WNT_BETA_CATENIN_SIGNALING-0.290
- ESTROGEN_RESPONSE_EARLY-0.210
- KRAS_SIGNALING_DN-0.180
- UV_RESPONSE_DN-0.150
- ESTROGEN_RESPONSE_LATE-0.130
- NOTCH_SIGNALING-0.130
- MYOGENESIS-0.100
- APICAL_SURFACE-0.090
- PANCREAS_BETA_CELLS-0.050
- HEDGEHOG_SIGNALING-0.010
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-E7-A7DV-01A-11R-A33J-07 | — | — | 0.910 |
| 2 | ERR2208974 | — | — | 0.906 |
| 3 | B8AED170-C88C-4A86-8377-93B5D14AB334 | — | — | 0.898 |
| 4 | 97A8E2B1-059B-4527-8FB4-116F718FFD16 | — | — | 0.894 |
| 5 | 3E499D12-B08A-491C-98C6-19EA420BDC99 | — | — | 0.893 |
| 6 | e5ae4a47-9a0d-4a70-a7be-40bddeb3d017 | — | — | 0.893 |
| 7 | 647EE729-B34A-41F0-85AB-207F8C24420B | — | — | 0.886 |
| 8 | f5174c29-918d-4ad9-bd44-c94463396414 | — | — | 0.884 |
| 9 | BDBF3ACE-7DC0-47C1-9B03-E2EDCF0B6CE6 | — | — | 0.884 |
| 10 | 70203945-80F8-4FA7-8C99-FEBAD3374103 | — | — | 0.883 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 40 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.640 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.600 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.490 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.490 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.450 | Idelalisib | — uncovered |
| PROTEIN_SECRETION | 0.450 | Remibrutinib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.420 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.410 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.390 | Inavolisib | — uncovered |
| APOPTOSIS | 0.380 | Idelalisib | — uncovered |
| COMPLEMENT | 0.380 | Inavolisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.370 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.320 | Inavolisib | — uncovered |
| ADIPOGENESIS | 0.310 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.300 | Inavolisib | — uncovered |
| E2F_TARGETS | 0.280 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.240 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.230 | Remibrutinib | — uncovered |
| FATTY_ACID_METABOLISM | 0.230 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |